EUVIMEDOdkrijte EUVIMED
Open access · CC BY 4.0

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4 ‐Mediated Immune Evasion in Acute Monocytic Leukaemia

Fangfang Huang, Xiang Luo, Mengyu Zhang, Le Jin, Wenxin Sun, Peihan Chen, Xiuli Hong, Chenyu Xu, Meizhi Jiang, Die Hu, Bin Zhang, Shengwei Hu and 7 more

Cell Proliferation · 2026

DOI: 10.1111/cpr.70090 ↗

At a glance

Journal article in Cell Proliferation, 2026. Written by Fangfang Huang and 18 co-authors. Institution: School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China. Major MEDLINE topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Homoharringtonine, Leukemia, Monocytic, Acute, Receptors, Immunologic. Cited 3 times so far (Crossref); 65 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, National Key Research and Development Program of China, Shenzhen Science and Technology Innovation Commission.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of leukaemic cells to evade immune surveillance. In this study, we demonstrate that homoharringtonine (HHT), an FDA‐approved therapeutic agent for chronic myeloid leukaemia (CML), inhibits this immune evasion by targeting the FTO/m6A/LILRB4 signalling pathway in monocytic AML. Utilising RNA sequencing (RNA‐seq) and various functional assays, we reveal that HHT treatment significantly reduces LILRB4 expression at both the RNA and protein levels, suggesting that the effects of HHT on LILRB4 are distinct from its well‐established role as a protein synthesis inhibitor. Mechanistically, HHT treatment markedly increases global levels of RNA m6A in THP‐1 cells by promoting the degradation of FTO, which subsequently diminishes the expression of its downstream targets, MLL1 and LILRB4. Furthermore, in vitro and in vivo analyses employing monocytic AML cell lines, mouse‐derived AML xenograft models, and patient samples collectively support the conclusion that HHT suppresses immune evasion in monocytic AML by reducing LILRB4 expression. Importantly, the downregulation of LILRB4 resulting from HHT treatment enhances the susceptibility of THP‐1 cells to CD8 + T cell cytotoxicity, accompanied by increased markers of immune activation. Overall, our findings position HHT as a promising clinical agent for enhancing CD8 + T cell‐based cancer immunotherapy by mitigating immune evasion in monocytic AML.

Subjects

MeSH terms (MEDLINE)

Alpha-Ketoglutarate-Dependent Dioxygenase FTOHomoharringtonineLeukemia, Monocytic, AcuteReceptors, ImmunologicImmune EvasionMembrane GlycoproteinsHumansAnimalsMiceCell Line, TumorTHP-1 CellsSignal TransductionXenograft Model Antitumor Assays

Author keywords

N6‐methyladenosine (m6A)acute monocytic leukaemiafat mass and obesity‐associated (FTO)homoharringtonine (HHT)immune evasionleukocyte immunoglobulin‐like receptor B4 (LILRB4)

Substances

Alpha-Ketoglutarate-Dependent Dioxygenase FTOHomoharringtonineFTO protein, humanLILRB4 protein, humanReceptors, ImmunologicMembrane Glycoproteins

Authors and institutions

  • School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
  • Department of Hematology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • Xiamen University, Laboratory Animal Center, Xiamen University, Xiamen, China.
  • Institute of Cardiovascular Diseases, Xiamen Cardiovascular Hospital, School of Medicine, Xiamen University, Xiamen, China.
  • Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongq…
  • Shenzhen Research Institute of Xiamen University, Shenzhen, China.

ORCID profiles: Qiang Luo, Siming Chen

Funding

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Shenzhen Science and Technology Innovation Commission
  • Fujian Provincial Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • Nanqiang Outstanding Young Talents Program from Xiamen University
  • Joint Project of Pinnacle Disciplinary Group, the Second Affiliated Hospital of Chongqing Medical University
  • Science, Technology and Innovation Commission of Shenzhen Municipality

Cite

APA

Huang, F., Luo, X., Zhang, M., Jin, L., Sun, W., Chen, P., Hong, X., Xu, C., Jiang, M., Hu, D., Zhang, B., Hu, S., Yang, C., Gao, R., Zeng, J., Lu, Q., Luo, Q., Wu, J., & Chen, S. (2026). Homoharringtonine Promotes FTO Degradation to Suppress LILRB4 ‐Mediated Immune Evasion in Acute Monocytic Leukaemia. Cell Proliferation. https://doi.org/10.1111/cpr.70090

Vancouver

Huang F, Luo X, Zhang M, Jin L, Sun W, Chen P, et al. Homoharringtonine Promotes FTO Degradation to Suppress LILRB4 ‐Mediated Immune Evasion in Acute Monocytic Leukaemia. Cell Proliferation. 2026. doi:10.1111/cpr.70090

BibTeX
@article{Huang2026,
  author = {Huang, Fangfang and Luo, Xiang and Zhang, Mengyu and Jin, Le and Sun, Wenxin and Chen, Peihan and Hong, Xiuli and Xu, Chenyu and Jiang, Meizhi and Hu, Die and Zhang, Bin and Hu, Shengwei and Yang, Chuanjiang and Gao, Rui and Zeng, Jinzhang and Lu, Quanyi and Luo, Qiang and Wu, Jun and Chen, Siming},
  title = {Homoharringtonine Promotes FTO Degradation to Suppress LILRB4 ‐Mediated Immune Evasion in Acute Monocytic Leukaemia},
  journal = {Cell Proliferation},
  year = {2026},
  doi = {10.1111/cpr.70090}
}
Start for free →